| 1.67 -0.02 (-1.18%) | 09-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.35  |
1-year : | 2.62 |
| Resists | First : | 2.01 |
Second : | 2.25 |
| Pivot price | 1.9 |
|||
| Supports | First : | 1.62 |
Second : | 1.35 |
| MAs | MA(5) : | 1.77 |
MA(20) : | 1.94 |
| MA(100) : | 2.14 |
MA(250) : | 1.74  |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 3.2 |
D(3) : | 7.4 |
| RSI | RSI(14): 30.7 |
|||
| 52-week | High : | 3.03 | Low : | 0.43 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ IPSC ] has closed above bottom band by 3.4%. Bollinger Bands are 50.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.78 - 1.8 | 1.8 - 1.81 |
| Low: | 1.6 - 1.62 | 1.62 - 1.63 |
| Close: | 1.65 - 1.67 | 1.67 - 1.69 |
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
Sun, 20 Sep 2026
Century Therapeutics, Inc.(NasdaqCM: IPSC) added to S&P Global BMI Index - marketscreener.com
Thu, 17 Sep 2026
The Pipeline for iPSC-Derived Cell Therapeutics in 2026 - BioInformant
Wed, 09 Sep 2026
Automatic tax sale leaves Century Therapeutics (NASDAQ: IPSC) SVP with 504,565 shares - Stock Titan
Wed, 09 Sep 2026
Century Therapeutics Appoints Joseph Truitt to Board of Directors - Yahoo Finance
Wed, 12 Aug 2026
Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates - GlobeNewswire
Wed, 12 Aug 2026
FDA and Century Align on Type 1 Diabetes Therapy Trial Plan - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 181 (M) |
| Shares Float | 101 (M) |
| Held by Insiders | 8.1 (%) |
| Held by Institutions | 87.4 (%) |
| Shares Short | 29,370 (K) |
| Shares Short P.Month | 28,380 (K) |
| EPS | -0.94 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.28 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -23.6 % |
| Return on Equity (ttm) | -49.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.44 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.53 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -87 (M) |
| Levered Free Cash Flow | -50 (M) |
| PE Ratio | -1.8 |
| PEG Ratio | 0 |
| Price to Book value | 1.29 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.49 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|